A new drug is giving hope to patients with one of the most lethal forms of cancer.
WATCH KATRINA’S STORY BELOW
New drug doubles survival time for pancreatic cancer patients
Daraxonrasib is now available at Nebraska Medicine’s Fred and Pamela Buffett Cancer Center through an expanded access program. The drug is not yet FDA approved but is approved for use as an investigational drug, meaning it is still being tested. It is currently available only to patients who are no longer responding to chemotherapy.
Pancreatic cancer is usually diagnosed in stage 4, after it has spread. Survival rates with chemotherapy average about six months, says oncologist Kelsey Klute, but patients taking Daraxonrasib are living twice as long…